卵巢癌患者腹水和外周血中CA125和CD4+CD25+调节性T细胞含量监测的临床价值被引量：6

导出

摘要目的探讨卵巢癌患者腹水和外周血中CA125、CD4^(+)CD25^(+)调节性T(Treg)细胞的差异,分析其在卵巢癌患者腹腔微环境中的作用和意义.方法采集该院妇科2018年3月-2020年5月卵巢癌患者的腹水标本和对应外周血标本23例,均经病理诊断或细胞学诊断证实.其中未接受任何治疗患者标本(PD)5例,卡铂和多西他赛联合静脉化疗6个疗程结束后3周患者标本(AC)11例,复发患者标本(RD)7例.流式细胞术分析CD4^(+)CD25^(+)Treg细胞百分比,酶联免疫法测定CA125水平.比较处于初治(PD)、化疗后(AC)及复发(RD)阶段卵巢癌患者的腹水、外周血中Treg细胞和CA125含量的差异.结果不同阶段卵巢癌患者腹水中Treg细胞百分比、CA125含量与同期的外周血标本、不同时期Treg细胞百分比及CA125含量差异均有统计学意义(均P<0.05).RD期含量最高,PD期含量最低.结论卵巢恶性肿瘤患者腹水在不同阶段CA125和Treg含量变化在临床预后评估中具有重要意义.

作者李晓峰张锐李金玲

机构地区吉林省人民医院吉林省肝胆病医院 [

出处《中国妇幼保健》 CAS 2021年第14期3199-3200,共2页 Maternal and Child Health Care of China

关键词卵巢癌腹水化疗敏感性 CA125 调节性T细胞

分类号 R737.31 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

1李荔枝,谭亚琴.卵巢癌分子标志物及靶向治疗的研究进展[J].癌症进展,2021,19(7):665-670. 被引量：6
2董林,齐笛,何佳婧,李予南.血清肿瘤标志物对胃癌患者术后复发转移的预测价值及影响因素分析[J].癌症进展,2021,19(8):798-801. 被引量：13
3刘永霞,寿好长.CA199、CA125联合检测在卵巢肿块鉴别及病情判断中的价值[J].中国妇幼保健,2018,33(1):64-66. 被引量：11
4董动丽,顾劲松,赵绍杰,唐艳,赵婷婷.血清HE4、CA125检测及ROMA模型在卵巢癌诊断中的应用价值[J].重庆医学,2017,46(5):577-579. 被引量：40
5武文华,王贺,崔满华.CD4^+CD25^+调节性T细胞与卵巢癌的相关研究进展[J].中国妇幼保健,2016,31(15):3192-3195. 被引量：2
6李珂,安宁.血清胸腺激酶1、CA125监测在中晚期卵巢癌患者化疗中的临床意义[J].四川医学,2020,41(8):835-838. 被引量：7
7毛柳.卵巢癌腹水及外周血CD4^+ CD25^+ Treg/CD4^+T细胞含量及其意义分析[J].中国妇幼保健,2016,31(22):4871-4874. 被引量：10
8姚海荣,田菁,李迎春,张文琪,郝权.卵巢癌患者腹水及外周血CD4＋ CD25＋调节性T细胞含量及抑制功能的研究[J].中国肿瘤临床,2014,41(12):787-792. 被引量：11

二级参考文献69

1Leffers N, Gooden MJ, deJong RA, et al. Prognostic significance oftumor--infiltrating T-lymphocytes in primary and metastatic le- sions of advanced stage ovarian cancer[J]. Cancer Immunol Immu- nother, 2009, 58(3):449-459.
2Savage PA, Malchow S, Levendlal DS. Basic principles of tu- mor-associated regulatory T cell biology[J]. Trends Immunol, 2013, 34(1) :33-40.
3Strauss L, Bergnann C, Gooding W, et al. The frequency and sup- pressor function of CD4+ CD25 high Foxp3+ T cells in the circula- tion of patients with squamous cell carcinoma of the head and neck [J]. Clin Cancer Res, 2007, 13(21):6301-6311.
4Preston GC, Goode EL, Hartmann LC, et al. Immunity and im- mune suppression in human ovarian cancer[J]. Immunotherapy, 2011, 3(4): 539-556.
5Tanaka H, Tanaka I, Kjaergaard I, et aI. Depletion of CD+CD25+ regulatory T cells augments the generation of specific immune T cella in tumor-draining lymph nodes[J].J Immunother, 2002, 25(3):207.
6Dowlatshahi M, Huang V, Gehad AE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses[J]. J Invest Der- matol, 2013, 133(7):1879-1889.
7Gupta R, BabbJS, Singh B, et al. The numbers of FoxP3+ lympho- cytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal stares[J]. Cancer Invest, 2011, 29(6):419-425.
8Curiel TJ, Coukos G, Zou L, et al. Specific recruiunent of regulato- ry T cells in ovarian carcinoma fosters immune privilege and pre- dicts reduced surviva[J]. Nat Med, 2004, 10(9):942-949.
9Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involve- ment of regulatory T cells in disease progression[J]. Cancer, 2003, 98 (5) : 1089-1 099.
10Chang DK, SuiJ, Geng S, et al. Humanization of an anti-CGR4 an- tibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells[J]. Mol Cancer Ther, 2012, 11(11):2451-2461.